enGene Holdings Inc. (NASDAQ:ENGN) Receives $25.22 Consensus PT from Brokerages

Shares of enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) have earned a consensus recommendation of "Buy" from the nine ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $24.13.

ENGN has been the topic of a number of analyst reports. Morgan Stanley decreased their target price on shares of enGene from $37.00 to $34.00 and set an "overweight" rating on the stock in a report on Tuesday, March 11th. JMP Securities reaffirmed a "market outperform" rating and issued a $18.00 price target on shares of enGene in a report on Monday, December 23rd. HC Wainwright reaffirmed a "buy" rating and issued a $25.00 price target on shares of enGene in a report on Tuesday, March 11th. Piper Sandler began coverage on shares of enGene in a research report on Tuesday, February 18th. They issued an "overweight" rating and a $26.00 price objective on the stock. Finally, UBS Group lowered shares of enGene from a "buy" rating to a "neutral" rating and dropped their target price for the company from $34.00 to $7.00 in a research report on Friday, February 14th.

enGene Price Performance

ENGN stock remained flat at $4.00 during mid-day trading on Thursday. The company's stock had a trading volume of 44,746 shares, compared to its average volume of 131,212. The company has a 50-day moving average price of $5.21 and a two-hundred day moving average price of $6.76. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. enGene has a 1-year low of $3.50 and a 1-year high of $16.62. The stock has a market capitalization of $203.91 million, a P/E ratio of -6.90 and a beta of -0.38.

Remove Ads

Institutional Trading of enGene

Hedge funds have recently added to or reduced their stakes in the business. Toronto Dominion Bank bought a new position in shares of enGene during the fourth quarter valued at about $97,000. VR Adviser LLC increased its stake in enGene by 41.5% in the 4th quarter. VR Adviser LLC now owns 5,046,414 shares of the company's stock worth $33,559,000 after purchasing an additional 1,480,573 shares during the period. Vestal Point Capital LP bought a new stake in enGene in the fourth quarter valued at approximately $2,460,000. Sphera Funds Management LTD. bought a new stake in enGene in the fourth quarter valued at approximately $3,724,000. Finally, Point72 Asset Management L.P. boosted its stake in shares of enGene by 84.7% during the fourth quarter. Point72 Asset Management L.P. now owns 1,224,797 shares of the company's stock valued at $8,145,000 after purchasing an additional 561,797 shares during the period. 64.16% of the stock is owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.